Latest RYMAN HEALTHCARE (ASX:RYM) News

A single exploration name blew the doors off the leaderboard, while two well-known uranium plays and a Nevada explorer sank hard. Behind the noise: deals got closer to completion, big raisings reset prices, and several “good news” gaps didn’t survive the week.

A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.

Ryman Healthcare has unveiled a refreshed strategy focused on growing recurring earnings and optimising its portfolio, targeting a $150 million sustainable cash flow improvement and $500 million cash release by FY29. The company plans to resume dividends from FY28, underpinned by a resilient balance sheet and disciplined capital management.

Ryman Healthcare reported a 13% revenue increase to NZD 413.8 million for H1 2025, yet swung to a significant net loss of NZD 45.2 million and suspended dividends, raising questions about its financial trajectory.

Ryman Healthcare reports a significant financial turnaround with its first positive free cash flow in over ten years, alongside upgraded sales and cost-saving targets for FY26 and completion of a major NZD 2 billion refinancing.

Ryman Healthcare has reported its first positive free cash flow in over a decade, driven by cost reductions and stronger sales momentum, while upgrading its sales guidance for FY26.

Ryman Healthcare has completed a full refinancing of its $2 billion syndicated loan facilities, extending the average maturity to five years and enhancing funding flexibility. The move aligns with the company’s disciplined growth strategy and sets the stage for future capital management decisions.